nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—epithelium—colon cancer	0.00983	0.123	CbGeAlD
Rasagiline—BCL2—smooth muscle tissue—colon cancer	0.00948	0.118	CbGeAlD
Rasagiline—BCL2—renal system—colon cancer	0.00912	0.114	CbGeAlD
Rasagiline—BCL2—lymphoid tissue—colon cancer	0.00757	0.0947	CbGeAlD
Rasagiline—BCL2—digestive system—colon cancer	0.00748	0.0935	CbGeAlD
Rasagiline—BCL2—bone marrow—colon cancer	0.0069	0.0862	CbGeAlD
Rasagiline—MAOB—embryo—colon cancer	0.00502	0.0627	CbGeAlD
Rasagiline—BCL2—lymph node—colon cancer	0.00427	0.0534	CbGeAlD
Rasagiline—MAOB—renal system—colon cancer	0.0038	0.0475	CbGeAlD
Rasagiline—MAOB—digestive system—colon cancer	0.00311	0.0389	CbGeAlD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—BAX—colon cancer	0.00289	0.0078	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—MYC—colon cancer	0.0028	0.00754	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—BAX—colon cancer	0.00277	0.00747	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.00277	0.00746	CbGpPWpGaD
Rasagiline—MAOB—vagina—colon cancer	0.00275	0.0344	CbGeAlD
Rasagiline—BCL2—IL-3 Signaling Pathway—BCL2L1—colon cancer	0.00272	0.00731	CbGpPWpGaD
Rasagiline—CYP1A2—renal system—colon cancer	0.0027	0.0338	CbGeAlD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—BCL2L1—colon cancer	0.00267	0.0072	CbGpPWpGaD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—BCL2L1—colon cancer	0.00251	0.00677	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—DCC—colon cancer	0.00251	0.00675	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—BCL2L1—colon cancer	0.00241	0.00648	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MSH2—colon cancer	0.00239	0.00643	CbGpPWpGaD
Rasagiline—BCL2—Activation of BAD and translocation to mitochondria—AKT1—colon cancer	0.00234	0.00632	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CHST4—colon cancer	0.00234	0.00632	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—BCL2L1—colon cancer	0.00234	0.0063	CbGpPWpGaD
Rasagiline—MAOB—liver—colon cancer	0.00232	0.029	CbGeAlD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP3—colon cancer	0.0023	0.00621	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—colon cancer	0.0023	0.00619	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.00225	0.00605	CbGpPWpGaD
Rasagiline—CYP1A2—digestive system—colon cancer	0.00222	0.0277	CbGeAlD
Rasagiline—MAOB—Alpha-synuclein signaling—SRC—colon cancer	0.00217	0.00585	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—colon cancer	0.00217	0.00585	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MLH1—colon cancer	0.00215	0.00579	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.00212	0.00571	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—CASP3—colon cancer	0.00206	0.00554	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—CASP3—colon cancer	0.00206	0.00554	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—PIK3CA—colon cancer	0.00204	0.00549	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BAX—colon cancer	0.00203	0.00547	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—MYC—colon cancer	0.00194	0.00523	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—BAX—colon cancer	0.00191	0.00513	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—CASP3—colon cancer	0.0019	0.00512	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—colon cancer	0.00185	0.00497	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—CASP3—colon cancer	0.00183	0.00493	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.00178	0.00481	CbGpPWpGaD
Rasagiline—MAOB—lymph node—colon cancer	0.00178	0.0222	CbGeAlD
Rasagiline—BCL2—Apoptosis—BCL2L1—colon cancer	0.00176	0.00475	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—CDKN1A—colon cancer	0.00172	0.00464	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—AKT1—colon cancer	0.00167	0.00449	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—BCL2L1—colon cancer	0.00165	0.00446	CbGpPWpGaD
Rasagiline—CYP1A2—liver—colon cancer	0.00165	0.0206	CbGeAlD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—BAX—colon cancer	0.00165	0.00444	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—PIK3CA—colon cancer	0.00165	0.00444	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—MYC—colon cancer	0.00164	0.00442	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—SRC—colon cancer	0.0016	0.0043	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—AKT1—colon cancer	0.00156	0.0042	CbGpPWpGaD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—colon cancer	0.00155	0.00419	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—MYC—colon cancer	0.00154	0.00416	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—CASP3—colon cancer	0.00149	0.00401	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—MYC—colon cancer	0.00148	0.004	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—SRC—colon cancer	0.00146	0.00394	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—HRAS—colon cancer	0.00145	0.0039	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MYC—colon cancer	0.00143	0.00385	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.00143	0.00384	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TGFB1—colon cancer	0.00143	0.00384	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—KRAS—colon cancer	0.00143	0.00384	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CCND1—colon cancer	0.00141	0.0038	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—PIK3CA—colon cancer	0.00139	0.00375	CbGpPWpGaD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—colon cancer	0.00139	0.00375	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—BRAF—colon cancer	0.00135	0.00365	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—BAX—colon cancer	0.00135	0.00364	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCND1—colon cancer	0.00134	0.0036	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—colon cancer	0.00133	0.00359	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CA7—colon cancer	0.00133	0.00359	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—colon cancer	0.00132	0.00356	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—colon cancer	0.00132	0.00356	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—colon cancer	0.00131	0.00352	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—colon cancer	0.0013	0.00351	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—EP300—colon cancer	0.0013	0.00349	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—EP300—colon cancer	0.0013	0.00349	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN1A—colon cancer	0.00129	0.00348	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BAX—colon cancer	0.00127	0.00342	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—SRC—colon cancer	0.00126	0.0034	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—APC—colon cancer	0.00126	0.00339	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BAX—colon cancer	0.00124	0.00335	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—EP300—colon cancer	0.00123	0.00332	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—BRAF—colon cancer	0.00122	0.00328	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—colon cancer	0.00121	0.00327	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—colon cancer	0.00118	0.00317	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—colon cancer	0.00117	0.00316	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—BCL2L1—colon cancer	0.00117	0.00316	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—colon cancer	0.00117	0.00314	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—AKT1—colon cancer	0.00114	0.00307	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—colon cancer	0.00112	0.00302	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—colon cancer	0.00112	0.00302	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—AKT1—colon cancer	0.00111	0.003	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.00111	0.003	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.00109	0.00295	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—colon cancer	0.00109	0.00294	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BCL2L1—colon cancer	0.00108	0.00291	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PIK3CA—colon cancer	0.00108	0.0029	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CHST5—colon cancer	0.00108	0.0029	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—colon cancer	0.00107	0.00289	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—AKT1—colon cancer	0.00107	0.00288	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—colon cancer	0.00106	0.00286	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.00106	0.00284	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.00105	0.00284	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—PIK3CA—colon cancer	0.00103	0.00277	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—colon cancer	0.00103	0.00277	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—APC—colon cancer	0.00103	0.00277	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—AKT1—colon cancer	0.00103	0.00277	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1A—colon cancer	0.00103	0.00277	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CASP3—colon cancer	0.00102	0.00276	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CASP3—colon cancer	0.00101	0.00273	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—colon cancer	0.000998	0.00269	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—colon cancer	0.000991	0.00267	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—colon cancer	0.000991	0.00267	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—colon cancer	0.000978	0.00263	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—EP300—colon cancer	0.000978	0.00263	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—colon cancer	0.000953	0.00257	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—APC—colon cancer	0.000949	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—colon cancer	0.000925	0.00249	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—colon cancer	0.000915	0.00246	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.00091	0.00245	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—colon cancer	0.000909	0.00245	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000891	0.0024	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—colon cancer	0.000888	0.00239	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—colon cancer	0.000881	0.00237	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—colon cancer	0.000873	0.00235	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—colon cancer	0.000862	0.00232	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1A—colon cancer	0.00086	0.00232	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—colon cancer	0.000854	0.0023	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—colon cancer	0.000852	0.0023	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—colon cancer	0.000852	0.0023	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1A—colon cancer	0.000834	0.00225	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ODC1—colon cancer	0.000807	0.00217	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CHST5—colon cancer	0.000807	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—colon cancer	0.000806	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—BCL10—colon cancer	0.000806	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000803	0.00216	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—SRC—colon cancer	0.000795	0.00214	CbGpPWpGaD
Rasagiline—Malaise—Irinotecan—colon cancer	0.00079	0.00144	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—colon cancer	0.00079	0.00213	CbGpPWpGaD
Rasagiline—Vertigo—Irinotecan—colon cancer	0.000787	0.00144	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—colon cancer	0.000787	0.00212	CbGpPWpGaD
Rasagiline—Dysuria—Capecitabine—colon cancer	0.000787	0.00143	CcSEcCtD
Rasagiline—Syncope—Irinotecan—colon cancer	0.000786	0.00143	CcSEcCtD
Rasagiline—Renal failure acute—Methotrexate—colon cancer	0.000785	0.00143	CcSEcCtD
Rasagiline—Leukopenia—Irinotecan—colon cancer	0.000785	0.00143	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—colon cancer	0.000784	0.00211	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000784	0.00211	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Capecitabine—colon cancer	0.000782	0.00143	CcSEcCtD
Rasagiline—Convulsion—Vincristine—colon cancer	0.00078	0.00142	CcSEcCtD
Rasagiline—Hypertension—Vincristine—colon cancer	0.000777	0.00142	CcSEcCtD
Rasagiline—Anaemia—Fluorouracil—colon cancer	0.000776	0.00141	CcSEcCtD
Rasagiline—Loss of consciousness—Irinotecan—colon cancer	0.00077	0.0014	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Methotrexate—colon cancer	0.000768	0.0014	CcSEcCtD
Rasagiline—Photosensitivity reaction—Capecitabine—colon cancer	0.000768	0.0014	CcSEcCtD
Rasagiline—Cough—Irinotecan—colon cancer	0.000765	0.00139	CcSEcCtD
Rasagiline—Weight decreased—Capecitabine—colon cancer	0.000762	0.00139	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—BRAF—colon cancer	0.000758	0.00204	CbGpPWpGaD
Rasagiline—Hypertension—Irinotecan—colon cancer	0.000757	0.00138	CcSEcCtD
Rasagiline—Leukopenia—Fluorouracil—colon cancer	0.000751	0.00137	CcSEcCtD
Rasagiline—Infestation—Capecitabine—colon cancer	0.000751	0.00137	CcSEcCtD
Rasagiline—Infestation NOS—Capecitabine—colon cancer	0.000751	0.00137	CcSEcCtD
Rasagiline—Depression—Capecitabine—colon cancer	0.000748	0.00136	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—colon cancer	0.000743	0.002	CbGpPWpGaD
Rasagiline—Acute coronary syndrome—Capecitabine—colon cancer	0.00074	0.00135	CcSEcCtD
Rasagiline—Cerebrovascular accident—Methotrexate—colon cancer	0.00074	0.00135	CcSEcCtD
Rasagiline—Discomfort—Irinotecan—colon cancer	0.000737	0.00134	CcSEcCtD
Rasagiline—Neuropathy peripheral—Capecitabine—colon cancer	0.000736	0.00134	CcSEcCtD
Rasagiline—Myocardial infarction—Capecitabine—colon cancer	0.000736	0.00134	CcSEcCtD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000734	0.00198	CbGpPWpGaD
Rasagiline—Stomatitis—Capecitabine—colon cancer	0.000732	0.00133	CcSEcCtD
Rasagiline—Jaundice—Capecitabine—colon cancer	0.000732	0.00133	CcSEcCtD
Rasagiline—Infection—Vincristine—colon cancer	0.00073	0.00133	CcSEcCtD
Rasagiline—Conjunctivitis—Capecitabine—colon cancer	0.00073	0.00133	CcSEcCtD
Rasagiline—Convulsion—Fluorouracil—colon cancer	0.000727	0.00133	CcSEcCtD
Rasagiline—Osteoarthritis—Methotrexate—colon cancer	0.000725	0.00132	CcSEcCtD
Rasagiline—Confusional state—Irinotecan—colon cancer	0.000721	0.00131	CcSEcCtD
Rasagiline—Nervous system disorder—Vincristine—colon cancer	0.00072	0.00131	CcSEcCtD
Rasagiline—Haematuria—Capecitabine—colon cancer	0.000716	0.0013	CcSEcCtD
Rasagiline—Chest pain—Fluorouracil—colon cancer	0.000715	0.0013	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—colon cancer	0.000711	0.00192	CbGpPWpGaD
Rasagiline—Infection—Irinotecan—colon cancer	0.000711	0.0013	CcSEcCtD
Rasagiline—Hyperhidrosis—Vincristine—colon cancer	0.00071	0.00129	CcSEcCtD
Rasagiline—Epistaxis—Capecitabine—colon cancer	0.000708	0.00129	CcSEcCtD
Rasagiline—Discomfort—Fluorouracil—colon cancer	0.000706	0.00129	CcSEcCtD
Rasagiline—Shock—Irinotecan—colon cancer	0.000704	0.00128	CcSEcCtD
Rasagiline—Nervous system disorder—Irinotecan—colon cancer	0.000702	0.00128	CcSEcCtD
Rasagiline—Anorexia—Vincristine—colon cancer	0.0007	0.00128	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—colon cancer	0.0007	0.00188	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—colon cancer	0.000692	0.00186	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Irinotecan—colon cancer	0.000692	0.00126	CcSEcCtD
Rasagiline—Confusional state—Fluorouracil—colon cancer	0.000691	0.00126	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—colon cancer	0.00069	0.00186	CbGpPWpGaD
Rasagiline—Mood swings—Methotrexate—colon cancer	0.000687	0.00125	CcSEcCtD
Rasagiline—Hypotension—Vincristine—colon cancer	0.000686	0.00125	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—CDKN1A—colon cancer	0.000683	0.00184	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000683	0.00184	CbGpPWpGaD
Rasagiline—Anorexia—Irinotecan—colon cancer	0.000682	0.00124	CcSEcCtD
Rasagiline—Ataxia—Methotrexate—colon cancer	0.000682	0.00124	CcSEcCtD
Rasagiline—Infection—Fluorouracil—colon cancer	0.000681	0.00124	CcSEcCtD
Rasagiline—Haemoglobin—Capecitabine—colon cancer	0.000677	0.00123	CcSEcCtD
Rasagiline—Rhinitis—Capecitabine—colon cancer	0.000676	0.00123	CcSEcCtD
Rasagiline—Haemorrhage—Capecitabine—colon cancer	0.000674	0.00123	CcSEcCtD
Rasagiline—Nervous system disorder—Fluorouracil—colon cancer	0.000672	0.00122	CcSEcCtD
Rasagiline—Hypoaesthesia—Capecitabine—colon cancer	0.00067	0.00122	CcSEcCtD
Rasagiline—Liver function test abnormal—Methotrexate—colon cancer	0.000669	0.00122	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—colon cancer	0.000669	0.0018	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Vincristine—colon cancer	0.000669	0.00122	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CASP3—colon cancer	0.000669	0.0018	CbGpPWpGaD
Rasagiline—Hypotension—Irinotecan—colon cancer	0.000668	0.00122	CcSEcCtD
Rasagiline—Urinary tract disorder—Capecitabine—colon cancer	0.000665	0.00121	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000664	0.00179	CbGpPWpGaD
Rasagiline—Insomnia—Vincristine—colon cancer	0.000664	0.00121	CcSEcCtD
Rasagiline—Oedema peripheral—Capecitabine—colon cancer	0.000664	0.00121	CcSEcCtD
Rasagiline—Connective tissue disorder—Capecitabine—colon cancer	0.000662	0.00121	CcSEcCtD
Rasagiline—Urethral disorder—Capecitabine—colon cancer	0.000661	0.0012	CcSEcCtD
Rasagiline—Paraesthesia—Vincristine—colon cancer	0.00066	0.0012	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000658	0.00177	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—colon cancer	0.000656	0.00177	CbGpPWpGaD
Rasagiline—Anorexia—Fluorouracil—colon cancer	0.000653	0.00119	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—EP300—colon cancer	0.00065	0.00175	CbGpPWpGaD
Rasagiline—Insomnia—Irinotecan—colon cancer	0.000647	0.00118	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CTNNB1—colon cancer	0.000644	0.00174	CbGpPWpGaD
Rasagiline—Paraesthesia—Irinotecan—colon cancer	0.000642	0.00117	CcSEcCtD
Rasagiline—Hypotension—Fluorouracil—colon cancer	0.00064	0.00117	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—colon cancer	0.000639	0.00172	CbGpPWpGaD
Rasagiline—Decreased appetite—Vincristine—colon cancer	0.000639	0.00116	CcSEcCtD
Rasagiline—Dyspnoea—Irinotecan—colon cancer	0.000638	0.00116	CcSEcCtD
Rasagiline—Somnolence—Irinotecan—colon cancer	0.000636	0.00116	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Vincristine—colon cancer	0.000634	0.00116	CcSEcCtD
Rasagiline—Eye disorder—Capecitabine—colon cancer	0.00063	0.00115	CcSEcCtD
Rasagiline—Dyspepsia—Irinotecan—colon cancer	0.00063	0.00115	CcSEcCtD
Rasagiline—Constipation—Vincristine—colon cancer	0.000628	0.00114	CcSEcCtD
Rasagiline—Asthma—Methotrexate—colon cancer	0.000627	0.00114	CcSEcCtD
Rasagiline—Cardiac disorder—Capecitabine—colon cancer	0.000625	0.00114	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000624	0.00114	CcSEcCtD
Rasagiline—Decreased appetite—Irinotecan—colon cancer	0.000622	0.00113	CcSEcCtD
Rasagiline—Insomnia—Fluorouracil—colon cancer	0.00062	0.00113	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Irinotecan—colon cancer	0.000618	0.00113	CcSEcCtD
Rasagiline—Paraesthesia—Fluorouracil—colon cancer	0.000615	0.00112	CcSEcCtD
Rasagiline—Constipation—Irinotecan—colon cancer	0.000612	0.00111	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000612	0.00165	CbGpPWpGaD
Rasagiline—Angiopathy—Capecitabine—colon cancer	0.000611	0.00111	CcSEcCtD
Rasagiline—Dyspnoea—Fluorouracil—colon cancer	0.000611	0.00111	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000609	0.00164	CbGpPWpGaD
Rasagiline—Somnolence—Fluorouracil—colon cancer	0.000609	0.00111	CcSEcCtD
Rasagiline—Immune system disorder—Capecitabine—colon cancer	0.000609	0.00111	CcSEcCtD
Rasagiline—Mediastinal disorder—Capecitabine—colon cancer	0.000607	0.00111	CcSEcCtD
Rasagiline—Chills—Capecitabine—colon cancer	0.000605	0.0011	CcSEcCtD
Rasagiline—Dyspepsia—Fluorouracil—colon cancer	0.000603	0.0011	CcSEcCtD
Rasagiline—Gastrointestinal pain—Vincristine—colon cancer	0.000601	0.00109	CcSEcCtD
Rasagiline—Decreased appetite—Fluorouracil—colon cancer	0.000596	0.00109	CcSEcCtD
Rasagiline—Alopecia—Capecitabine—colon cancer	0.000595	0.00109	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000591	0.00108	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—colon cancer	0.000591	0.00159	CbGpPWpGaD
Rasagiline—Mental disorder—Capecitabine—colon cancer	0.00059	0.00108	CcSEcCtD
Rasagiline—Feeling abnormal—Irinotecan—colon cancer	0.000589	0.00107	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—colon cancer	0.000587	0.00158	CbGpPWpGaD
Rasagiline—Malnutrition—Capecitabine—colon cancer	0.000587	0.00107	CcSEcCtD
Rasagiline—Dysuria—Methotrexate—colon cancer	0.000586	0.00107	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—colon cancer	0.000585	0.00158	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Irinotecan—colon cancer	0.000585	0.00107	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Methotrexate—colon cancer	0.000582	0.00106	CcSEcCtD
Rasagiline—Abdominal pain—Vincristine—colon cancer	0.000581	0.00106	CcSEcCtD
Rasagiline—Body temperature increased—Vincristine—colon cancer	0.000581	0.00106	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.000579	0.00156	CbGpPWpGaD
Rasagiline—Flatulence—Capecitabine—colon cancer	0.000578	0.00105	CcSEcCtD
Rasagiline—Erectile dysfunction—Methotrexate—colon cancer	0.000577	0.00105	CcSEcCtD
Rasagiline—Dysgeusia—Capecitabine—colon cancer	0.000574	0.00105	CcSEcCtD
Rasagiline—Photosensitivity reaction—Methotrexate—colon cancer	0.000572	0.00104	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—colon cancer	0.000568	0.00153	CbGpPWpGaD
Rasagiline—Back pain—Capecitabine—colon cancer	0.000567	0.00103	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000566	0.00152	CbGpPWpGaD
Rasagiline—Body temperature increased—Irinotecan—colon cancer	0.000565	0.00103	CcSEcCtD
Rasagiline—Abdominal pain—Irinotecan—colon cancer	0.000565	0.00103	CcSEcCtD
Rasagiline—Feeling abnormal—Fluorouracil—colon cancer	0.000565	0.00103	CcSEcCtD
Rasagiline—Muscle spasms—Capecitabine—colon cancer	0.000564	0.00103	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—colon cancer	0.00056	0.00151	CbGpPWpGaD
Rasagiline—Infestation—Methotrexate—colon cancer	0.000559	0.00102	CcSEcCtD
Rasagiline—Infestation NOS—Methotrexate—colon cancer	0.000559	0.00102	CcSEcCtD
Rasagiline—Depression—Methotrexate—colon cancer	0.000557	0.00102	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—EGFR—colon cancer	0.000554	0.00149	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—colon cancer	0.000553	0.00149	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000551	0.00148	CbGpPWpGaD
Rasagiline—Tremor—Capecitabine—colon cancer	0.00055	0.001	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—colon cancer	0.000549	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—colon cancer	0.000548	0.00147	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000545	0.00147	CbGpPWpGaD
Rasagiline—Stomatitis—Methotrexate—colon cancer	0.000545	0.000993	CcSEcCtD
Rasagiline—Ill-defined disorder—Capecitabine—colon cancer	0.000544	0.000992	CcSEcCtD
Rasagiline—Urticaria—Fluorouracil—colon cancer	0.000544	0.000992	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—colon cancer	0.000543	0.00146	CbGpPWpGaD
Rasagiline—Conjunctivitis—Methotrexate—colon cancer	0.000543	0.00099	CcSEcCtD
Rasagiline—Anaemia—Capecitabine—colon cancer	0.000542	0.000988	CcSEcCtD
Rasagiline—Body temperature increased—Fluorouracil—colon cancer	0.000542	0.000987	CcSEcCtD
Rasagiline—Hypersensitivity—Vincristine—colon cancer	0.000541	0.000986	CcSEcCtD
Rasagiline—Sweating—Methotrexate—colon cancer	0.000536	0.000976	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000533	0.00144	CbGpPWpGaD
Rasagiline—Haematuria—Methotrexate—colon cancer	0.000533	0.000971	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000533	0.00143	CbGpPWpGaD
Rasagiline—Malaise—Capecitabine—colon cancer	0.000529	0.000964	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—colon cancer	0.000527	0.000961	CcSEcCtD
Rasagiline—Vertigo—Capecitabine—colon cancer	0.000527	0.00096	CcSEcCtD
Rasagiline—Hypersensitivity—Irinotecan—colon cancer	0.000527	0.00096	CcSEcCtD
Rasagiline—Asthenia—Vincristine—colon cancer	0.000527	0.00096	CcSEcCtD
Rasagiline—Syncope—Capecitabine—colon cancer	0.000526	0.000959	CcSEcCtD
Rasagiline—Leukopenia—Capecitabine—colon cancer	0.000525	0.000957	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000521	0.0014	CbGpPWpGaD
Rasagiline—Loss of consciousness—Capecitabine—colon cancer	0.000516	0.00094	CcSEcCtD
Rasagiline—Asthenia—Irinotecan—colon cancer	0.000513	0.000935	CcSEcCtD
Rasagiline—Cough—Capecitabine—colon cancer	0.000512	0.000933	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000507	0.00137	CbGpPWpGaD
Rasagiline—Hypertension—Capecitabine—colon cancer	0.000506	0.000923	CcSEcCtD
Rasagiline—Hypersensitivity—Fluorouracil—colon cancer	0.000505	0.00092	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—colon cancer	0.000504	0.000919	CcSEcCtD
Rasagiline—Diarrhoea—Vincristine—colon cancer	0.000503	0.000916	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—colon cancer	0.000502	0.000914	CcSEcCtD
Rasagiline—Chest pain—Capecitabine—colon cancer	0.000499	0.00091	CcSEcCtD
Rasagiline—Arthralgia—Capecitabine—colon cancer	0.000499	0.00091	CcSEcCtD
Rasagiline—Anxiety—Capecitabine—colon cancer	0.000498	0.000907	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000496	0.000904	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—colon cancer	0.000495	0.000903	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—SRC—colon cancer	0.000495	0.00133	CbGpPWpGaD
Rasagiline—Discomfort—Capecitabine—colon cancer	0.000493	0.000899	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000493	0.00133	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000492	0.00133	CbGpPWpGaD
Rasagiline—Urethral disorder—Methotrexate—colon cancer	0.000492	0.000896	CcSEcCtD
Rasagiline—Diarrhoea—Irinotecan—colon cancer	0.000489	0.000892	CcSEcCtD
Rasagiline—Dry mouth—Capecitabine—colon cancer	0.000488	0.00089	CcSEcCtD
Rasagiline—Dizziness—Vincristine—colon cancer	0.000486	0.000885	CcSEcCtD
Rasagiline—Pruritus—Fluorouracil—colon cancer	0.000485	0.000883	CcSEcCtD
Rasagiline—Confusional state—Capecitabine—colon cancer	0.000483	0.00088	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—colon cancer	0.000482	0.0013	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.00048	0.00129	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—colon cancer	0.00048	0.00129	CbGpPWpGaD
Rasagiline—Infection—Capecitabine—colon cancer	0.000476	0.000867	CcSEcCtD
Rasagiline—Dizziness—Irinotecan—colon cancer	0.000473	0.000862	CcSEcCtD
Rasagiline—Shock—Capecitabine—colon cancer	0.000471	0.000858	CcSEcCtD
Rasagiline—Nervous system disorder—Capecitabine—colon cancer	0.00047	0.000856	CcSEcCtD
Rasagiline—BCL2—Immune System—BCL10—colon cancer	0.000469	0.00126	CbGpPWpGaD
Rasagiline—Eye disorder—Methotrexate—colon cancer	0.000469	0.000854	CcSEcCtD
Rasagiline—Diarrhoea—Fluorouracil—colon cancer	0.000469	0.000854	CcSEcCtD
Rasagiline—Vomiting—Vincristine—colon cancer	0.000467	0.000851	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—colon cancer	0.000466	0.000848	CcSEcCtD
Rasagiline—Skin disorder—Capecitabine—colon cancer	0.000465	0.000847	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—colon cancer	0.000465	0.00125	CbGpPWpGaD
Rasagiline—Rash—Vincristine—colon cancer	0.000463	0.000844	CcSEcCtD
Rasagiline—Hyperhidrosis—Capecitabine—colon cancer	0.000463	0.000843	CcSEcCtD
Rasagiline—Dermatitis—Vincristine—colon cancer	0.000463	0.000843	CcSEcCtD
Rasagiline—Headache—Vincristine—colon cancer	0.00046	0.000839	CcSEcCtD
Rasagiline—Anorexia—Capecitabine—colon cancer	0.000456	0.000832	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—colon cancer	0.000455	0.000829	CcSEcCtD
Rasagiline—Vomiting—Irinotecan—colon cancer	0.000455	0.000829	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.000453	0.00122	CbGpPWpGaD
Rasagiline—Immune system disorder—Methotrexate—colon cancer	0.000453	0.000826	CcSEcCtD
Rasagiline—Dizziness—Fluorouracil—colon cancer	0.000453	0.000826	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—colon cancer	0.000452	0.000824	CcSEcCtD
Rasagiline—Rash—Irinotecan—colon cancer	0.000451	0.000822	CcSEcCtD
Rasagiline—Dermatitis—Irinotecan—colon cancer	0.000451	0.000821	CcSEcCtD
Rasagiline—Chills—Methotrexate—colon cancer	0.00045	0.00082	CcSEcCtD
Rasagiline—Headache—Irinotecan—colon cancer	0.000448	0.000817	CcSEcCtD
Rasagiline—Hypotension—Capecitabine—colon cancer	0.000447	0.000815	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—colon cancer	0.000443	0.000808	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000442	0.00119	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000441	0.00119	CbGpPWpGaD
Rasagiline—Mental disorder—Methotrexate—colon cancer	0.000439	0.000801	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000438	0.00118	CbGpPWpGaD
Rasagiline—Malnutrition—Methotrexate—colon cancer	0.000437	0.000796	CcSEcCtD
Rasagiline—Nausea—Vincristine—colon cancer	0.000436	0.000795	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000436	0.000795	CcSEcCtD
Rasagiline—Vomiting—Fluorouracil—colon cancer	0.000436	0.000794	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—EGFR—colon cancer	0.000434	0.00117	CbGpPWpGaD
Rasagiline—Insomnia—Capecitabine—colon cancer	0.000433	0.000789	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000432	0.00116	CbGpPWpGaD
Rasagiline—Rash—Fluorouracil—colon cancer	0.000432	0.000787	CcSEcCtD
Rasagiline—Dermatitis—Fluorouracil—colon cancer	0.000432	0.000786	CcSEcCtD
Rasagiline—Paraesthesia—Capecitabine—colon cancer	0.00043	0.000783	CcSEcCtD
Rasagiline—Headache—Fluorouracil—colon cancer	0.000429	0.000782	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—colon cancer	0.000429	0.00115	CbGpPWpGaD
Rasagiline—Dysgeusia—Methotrexate—colon cancer	0.000428	0.000779	CcSEcCtD
Rasagiline—Dyspnoea—Capecitabine—colon cancer	0.000427	0.000778	CcSEcCtD
Rasagiline—Nausea—Irinotecan—colon cancer	0.000425	0.000774	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	0.000424	0.00114	CbGpPWpGaD
Rasagiline—Back pain—Methotrexate—colon cancer	0.000422	0.00077	CcSEcCtD
Rasagiline—Dyspepsia—Capecitabine—colon cancer	0.000421	0.000768	CcSEcCtD
Rasagiline—Decreased appetite—Capecitabine—colon cancer	0.000416	0.000758	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Capecitabine—colon cancer	0.000413	0.000753	CcSEcCtD
Rasagiline—Constipation—Capecitabine—colon cancer	0.000409	0.000746	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000408	0.0011	CbGpPWpGaD
Rasagiline—Nausea—Fluorouracil—colon cancer	0.000407	0.000742	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—colon cancer	0.000405	0.000738	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—colon cancer	0.000404	0.000736	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000396	0.00107	CbGpPWpGaD
Rasagiline—Feeling abnormal—Capecitabine—colon cancer	0.000395	0.000719	CcSEcCtD
Rasagiline—Malaise—Methotrexate—colon cancer	0.000394	0.000718	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—colon cancer	0.000392	0.000715	CcSEcCtD
Rasagiline—Gastrointestinal pain—Capecitabine—colon cancer	0.000391	0.000713	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—colon cancer	0.000391	0.000712	CcSEcCtD
Rasagiline—Cough—Methotrexate—colon cancer	0.000381	0.000694	CcSEcCtD
Rasagiline—Urticaria—Capecitabine—colon cancer	0.00038	0.000693	CcSEcCtD
Rasagiline—Body temperature increased—Capecitabine—colon cancer	0.000378	0.00069	CcSEcCtD
Rasagiline—Abdominal pain—Capecitabine—colon cancer	0.000378	0.00069	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—colon cancer	0.000378	0.00069	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—BCL2L1—colon cancer	0.000378	0.00102	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000377	0.00102	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000377	0.00102	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—colon cancer	0.000376	0.00101	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000375	0.00101	CbGpPWpGaD
Rasagiline—Chest pain—Methotrexate—colon cancer	0.000372	0.000678	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—colon cancer	0.000372	0.000678	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.00037	0.000996	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000369	0.000673	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—colon cancer	0.000367	0.000669	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000367	0.000988	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000367	0.000988	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000363	0.000977	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—colon cancer	0.000362	0.000975	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGFR3—colon cancer	0.000361	0.000972	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—colon cancer	0.000359	0.000655	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000357	0.000962	CbGpPWpGaD
Rasagiline—Infection—Methotrexate—colon cancer	0.000354	0.000645	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000353	0.00095	CbGpPWpGaD
Rasagiline—Hypersensitivity—Capecitabine—colon cancer	0.000353	0.000643	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—colon cancer	0.00035	0.000637	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—colon cancer	0.000348	0.000938	CbGpPWpGaD
Rasagiline—Skin disorder—Methotrexate—colon cancer	0.000346	0.000631	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—colon cancer	0.000345	0.000628	CcSEcCtD
Rasagiline—Asthenia—Capecitabine—colon cancer	0.000343	0.000626	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—colon cancer	0.00034	0.000619	CcSEcCtD
Rasagiline—Pruritus—Capecitabine—colon cancer	0.000339	0.000617	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—colon cancer	0.000333	0.000607	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000329	0.000885	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000328	0.000883	CbGpPWpGaD
Rasagiline—Diarrhoea—Capecitabine—colon cancer	0.000328	0.000597	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000325	0.000592	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—colon cancer	0.000322	0.000587	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000321	0.000866	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000321	0.000866	CbGpPWpGaD
Rasagiline—Paraesthesia—Methotrexate—colon cancer	0.00032	0.000583	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—colon cancer	0.000318	0.000579	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—colon cancer	0.000317	0.000577	CcSEcCtD
Rasagiline—Dizziness—Capecitabine—colon cancer	0.000317	0.000577	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—colon cancer	0.000314	0.000572	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—colon cancer	0.00031	0.000565	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—CA7—colon cancer	0.000308	0.00083	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Methotrexate—colon cancer	0.000308	0.000561	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—colon cancer	0.000308	0.000828	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000306	0.000825	CbGpPWpGaD
Rasagiline—Vomiting—Capecitabine—colon cancer	0.000304	0.000555	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000304	0.000818	CbGpPWpGaD
Rasagiline—Rash—Capecitabine—colon cancer	0.000302	0.00055	CcSEcCtD
Rasagiline—Dermatitis—Capecitabine—colon cancer	0.000302	0.00055	CcSEcCtD
Rasagiline—Headache—Capecitabine—colon cancer	0.0003	0.000547	CcSEcCtD
Rasagiline—Feeling abnormal—Methotrexate—colon cancer	0.000294	0.000535	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—colon cancer	0.000291	0.000531	CcSEcCtD
Rasagiline—Nausea—Capecitabine—colon cancer	0.000284	0.000518	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—colon cancer	0.000283	0.000516	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—colon cancer	0.000282	0.000513	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—colon cancer	0.000282	0.000513	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—colon cancer	0.000263	0.000479	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000258	0.000695	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—colon cancer	0.000257	0.000692	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—colon cancer	0.000256	0.000466	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—colon cancer	0.000252	0.00046	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—colon cancer	0.000244	0.000444	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—colon cancer	0.000236	0.000429	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—colon cancer	0.000227	0.000413	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CTNNB1—colon cancer	0.000225	0.000606	CbGpPWpGaD
Rasagiline—Rash—Methotrexate—colon cancer	0.000225	0.00041	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—colon cancer	0.000225	0.000409	CcSEcCtD
Rasagiline—Headache—Methotrexate—colon cancer	0.000223	0.000407	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1A—colon cancer	0.00022	0.000592	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—colon cancer	0.00022	0.000592	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCB1—colon cancer	0.000213	0.000574	CbGpPWpGaD
Rasagiline—Nausea—Methotrexate—colon cancer	0.000212	0.000386	CcSEcCtD
Rasagiline—BCL2—Immune System—FGFR3—colon cancer	0.00021	0.000566	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMS—colon cancer	0.000209	0.000564	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EP300—colon cancer	0.000209	0.000564	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—SRC—colon cancer	0.000204	0.000548	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NRAS—colon cancer	0.000196	0.000527	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ODC1—colon cancer	0.000187	0.000503	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CHST5—colon cancer	0.000187	0.000503	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—colon cancer	0.000178	0.00048	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—colon cancer	0.000178	0.000479	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—colon cancer	0.000169	0.000454	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—colon cancer	0.000155	0.000417	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—colon cancer	0.000148	0.000399	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—colon cancer	0.000143	0.000386	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—colon cancer	0.000131	0.000353	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—colon cancer	0.000128	0.000345	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—colon cancer	0.000126	0.000341	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—colon cancer	0.000122	0.000328	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—colon cancer	0.000119	0.000319	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—colon cancer	0.000117	0.000314	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—colon cancer	0.000114	0.000307	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—colon cancer	0.000104	0.00028	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—colon cancer	9.81e-05	0.000264	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—colon cancer	9.7e-05	0.000261	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—colon cancer	9.02e-05	0.000243	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—colon cancer	8.34e-05	0.000225	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.71e-05	0.000208	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—colon cancer	7.37e-05	0.000198	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—colon cancer	7.18e-05	0.000193	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.06e-05	0.000163	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—colon cancer	5.86e-05	0.000158	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.04e-05	0.000136	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—colon cancer	4.93e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—colon cancer	4.84e-05	0.00013	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.73e-05	0.0001	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—colon cancer	3.43e-05	9.24e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—colon cancer	2.7e-05	7.27e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—colon cancer	2.25e-05	6.05e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—colon cancer	1.66e-05	4.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—colon cancer	1.36e-05	3.65e-05	CbGpPWpGaD
